Dr. Pusztai on Challenges With Neoadjuvant HER2 Therapy

Lajos Pusztai, MD
Published: Tuesday, Nov 28, 2017



Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer

Pusztai says that one of the biggest challenges is understanding which patient needs what treatment—pertuzumab (Perjeta), trastuzumab (Herceptin), or chemotherapy.

Additionally, there are patients who are able to achieve a good response with fewer treatments, and those patients need to be selected, Pusztai adds.
 


Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer

Pusztai says that one of the biggest challenges is understanding which patient needs what treatment—pertuzumab (Perjeta), trastuzumab (Herceptin), or chemotherapy.

Additionally, there are patients who are able to achieve a good response with fewer treatments, and those patients need to be selected, Pusztai adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x